Global Gene Editing Market

Gene Editing Market Size, Share, Growth Analysis, By Technology ((CRISPR)/Cas9, TALENs/MegaTALs, ZFN, Meganucleases, and Others), By Delivery Method (Ex-Vivo and In-Vivo), By End Use (Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes, and Contract Research Organizations), By Region -Industry Forecast 2026-2033

Report ID: SQMIG35H2103 | Region: Global | Published Date: August, 2025
Pages: 178 |Tables: 91 |Figures: 71

To request a free sample copy of this report, please complete the form below.

Our Clients

  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt
  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt

    • FAQs

    Global Gene Editing Market size was valued at USD 4.64 Billion in 2024 poised to grow between USD 4.95 Billion in 2025 to USD 8.38 Billion by 2033, growing at a CAGR of 6.8% in the forecast period (2026–2033).

    The global gene editing market outlook is highly competitive, with key players including CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Sangamo Therapeutics, and Thermo Fisher Scientific. These companies focus on strategic partnerships, clinical advancements, and product development. For example, Intellia is advancing in-vivo CRISPR therapies, while Sangamo emphasizes zinc finger nuclease (ZFN) technology. Thermo Fisher expands its gene editing tool portfolio through acquisitions and innovation, strengthening its position in research and clinical applications. 'CRISPR Therapeutics (Switzerland)', 'Editas Medicine (USA)', 'Intellia Therapeutics (USA)', 'Sangamo Therapeutics (USA)', 'Thermo Fisher Scientific (USA)', 'Horizon Discovery (United Kingdom)', 'Cellectis (France)', 'Caribou Biosciences (USA)', 'Beam Therapeutics (USA)', 'Precision BioSciences (USA)', 'ToolGen Inc. (South Korea)', 'Takara Bio Inc. (Japan)', 'Agilent Technologies (USA)', 'Inscripta (USA)', 'Locus Biosciences (USA)'

    The growing emphasis on personalized medicine is driving the global gene editing market growth. By enabling precise genetic modifications, technologies like CRISPR allow tailored treatments for individual genetic profiles. This customization enhances treatment efficacy and minimizes side effects, leading pharmaceutical companies to invest heavily in gene editing tools to support targeted therapy development.

    Expansion of CRISPR-Based Therapeutics Pipeline: CRISPR-based therapeutics are advancing swiftly, with numerous candidates entering clinical trials targeting diseases like cancer and sickle cell anemia. Increased funding and early regulatory support are accelerating development. This surge reflects growing confidence in CRISPR’s clinical value and its transformative potential in personalized, disease-specific treatments.

    Which Sectors Benefit from Gene Editing Advancements in North America?

    Related Reports

    Genome Editing Market
    Buy Now GET FREE SAMPLE
    Gene Therapy Market
    Buy Now GET FREE SAMPLE
    Gene Synthesis Market
    Buy Now GET FREE SAMPLE
    Gene Amplification Technologies Market
    Buy Now GET FREE SAMPLE
    Cancer Gene Therapy Market
    Buy Now GET FREE SAMPLE
    Synthetic Biology Market
    Buy Now GET FREE SAMPLE
    DNA Synthesis Market
    Buy Now GET FREE SAMPLE
    CRISPR Technology Market
    Buy Now GET FREE SAMPLE

    Feedback From Our Clients

    Global Gene Editing Market

    Report ID: SQMIG35H2103

    $5,300
    BUY NOW